ABT vs PLUS · P/E 25, rev $44.33B vs P/E 17, rev $2.07B
Abbott Laboratories (ABT) versus ePlus inc (PLUS) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
ePlus inc (PLUS) is a software - application company listed on NASDAQ.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported PLUS revenue for 2025-03-31 was $2.07B. Net income was $108.0M. Revenue was down 7.0% from 2024-03-31 to 2025-03-31. PLUS currently screens at market cap $2.10B and trailing P/E 17.1.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. PLUS currently screens at market cap $2.10B and trailing P/E 17.1.
Not investment advice. Open the ABT and PLUS stock pages for the full models.
Not investment advice.